ArticleBMC cancer2025

The MCL elderly III trial protocol: an international, randomized, open-label phase II trial to investigate the combinations of venetoclax, ibrutinib and rituximab or bendamustine, ibrutinib and rituximab in patients with treatment naive mantle cell lymphoma not eligible for dose-intensive treatment.

Stephanie Herold et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.